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Summary Assessment of heterogeneity in oestrogen receptor (ER) expression aims to improve prediction of
prognosis and treatment assignment in breast cancer. Current assessments are performed manually and are
subjective. Automated image analysis as described here objectively quantitates ER in breast cancer nuclei
obtained by needle aspiration. ER was visualised by ERICA with diaminobenzidine (DAB) substrate. Various
indices of ER positivity were derived from the integrated density and average density measurements of
nuclear DAB. Each index was compensated for background staining by non-specific antibody binding and
endogenous peroxidase activity. Total nuclear ER content (iAntegrated optical density of stain) was strongly
associated with the biopsy ER concentration determined by shturation analysis of radioligand binding (DCC),
P < 0.005. Nuclear ER concentration by image analysis (mean optical density of stain) was not associated
with the DCC measurement of ER concentration, P> 0.05. This was attributed to technical artefacts of
cytocentrifugation. Using threshold values of 5% positive cells and 1Ofmol mg- 1, concordance of assignment
of ER status by image analysis with the DCC assay was 91%, sensitivity was 89% and specificity 100%. It
was concluded that image analysis is an appropriate, easy and economic method for determining the nuclear
ER status of aspirated cancer cells. Image analysis has the potential to become a powerful diagnostic tool in
the assessment of hormone receptor status of breast cancer patients.
The presence of oestrogen and progesterone receptors in
breast cancer tissue is now accepted as indicating a better
overall disease prognosis for the patient, and as a marker for
assisting the selection of patients who may benefit from
endocrine therapies (Cant et al., 1985; McGuire, 1987;
Thorpe et al., 1986; Williams et al., 1987).
However, the power of prediction for good clinical
endocrine response which is afforded by hormone receptor
quantitation could be improved considerably at the
individual patient level. The current feeling is that a
knowledge of the heterogeneity of nuclear oestrogen receptor
(ER) expression could be helpful in improving the reliability
of patient assessment, and thereby assist in the assignment of
appropriate treatment. Fine needle aspiration (FNA) biopsy
is a proven effective procedure for the diagnosis of
malignant diseases of the human breast (Orell et al., 1986),
and a simultaneous evaluation of FN aspirates for the
heterogeneity of oestrogen receptor expression within the
cancer cell population would yield an early assessment of
prognosis without recourse to surgery. The newly emerging
technique of video image analysis promises to remove much
of the subjectivity integral to semi-quantitative assessments
of immunocytochemical staining (Charpin et al., 1986).
Our aims in performing this study were: (1) to develop an
image analysis method to measure objectively heterogeneity
of ER expression by breast cancer nuclei in fine needle
aspirate; and (2) to compare the results from the image
analysis of FNA with the biochemically determined ER
concentration of the corresponding surgical biopsy for all
patients in the study.
Materials and methods
Tissues
Breast carcinoma tissue was collected for this study from 35
sequential surgical patients at Flinders Medical Centre. All
patients had primary breast cancer disease, and had received
no preoperative treatment. Biopsies were transported on ice
to the laboratory within 10 minutes of removal in theatre. A
representative sample of approximate dimension
1 x 10 x 0.5 cm was trimmed of fat for the hormone receptor
analyses.
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Preparation and ER staining offine needle aspirates
The tumours, originally diagnosed as malignant by FNA in
the breast clinic, were reaspirated on an ice-cold aluminium
block to provide source material for the video image
analysis. A 26 gauge needle with negative pressure applied
was passed through the surgical biopsy a minimum of six
times at varying angles and sites to ensure a representative
sample was taken, and the material collected was dispersed
into a 0.5 ml aliquot of RPMI 1640 medium (Gibco, NY) by
vortexing. Aspirated cells were then deposited on to poly-L-
lysine (Sigma, St Louis, MO) coated slides by cytocentrifuge.
The tumour cytospins were fixed and stained for the
presence of ER using an ERICA kit (Abbott Diagnostic
Labs, Chicago, IL) according to the manufacturer's
instructions. The cytospins were frequently stored between
the fixation and the staining steps for 24-48 h at -25°C in
the glycerol sucrose buffer recommended by the ERICA
instruction sheet. Counterstaining of the nuclei was achieved
using weak Haematoxylin (1:1 diluted Lillie Mayer's
Haematoxylin) for 30 s. The specimens were then dehydrated
and mounted for light microscopy. It is important to stress
that, before staining, care should be taken to prevent drying
of the specimen, since this results in a decrease in receptor
antigenicity.
Biochemical quantitation of oestrogen receptor
The surgical biopsy was snap frozen immediately after needle
aspiration and stored at -70°C for 24-48 h. Quantitation of
ER was by radioligand binding in a multipoint dextran-coated
charcoal assay with Scatchard analysis, as reported
previously (Horsfall et al., 1986). Receptor concentrations
were expressed as fmol mg-1 cytosol protein. Tumour
cytosols with an oestrogen receptor concentration equal to
or greater than 10 fmol mg-1 protein were graded as ER
positive in this study.
Video image analysis of ERICA stained aspirates
The video image analytical system used in this study was
developed in our laboratories (Jarvis, 1986, 1987, 1988). In
brief, the system comprises a microscope, solid state camera,
video digitiser, microcomputer and digitiser tablet (Jarvis,
1988). The image analysis software permits selection and
scoring of individual tumour cells through editing of debris,
overlapping or touching nuclei, stromal cells or any other
undesired feature. The editing functions are performed by a
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moving cursor operated manually through the linked
digitiser pad. Criteria for assigning malignant versus benign
to cellular elements were based on standard cytological
features, including nuclear/cytoplasmic ratio, nuclear pleo-
morphism and nuclear irregularity.
Sequential fields were systematically examined using a
x 40 objective and a x 5 camera eyepiece to assess a
minimum of 250 nuclei from both the primary ER
monoclonal antibody-stained and the control antibody-
stained cytospins. Each field was analysed alternately at two
wavelengths using interference filters of 550 nm (green)
50 nm bandwidth, and 436 nm (blue) 16 nm bandwidth. The
550 nm image allowed detection and editing of the total
number of nuclei present by virtue of the haematoxylin
counterstain. Those stained with the red-brown diamino-
benzidine (DAB) deposit were isolated by the 436 nm filter,
which reduced the absorbance contribution of the
haematoxylin dye to an undetectable level. Integrated optical
density (IOD) measurements at 436 nm were therefore
related to the total amount of DAB deposit in each nucleus.
To enable comparisons to be made between expression of
oestrogen receptor in terms of either total content per
nucleus or mean concentration per nucleus, the integrated
optical density measurement for each nucleus was divided by
its area to give an average optical density (OD) measurement
for that nucleus.
Various strategies were employed for calculating a
positivity index for nuclear ER from the integrated density
and average density measurements of nuclear DAB. Because
control antibody-stained nuclei often contain measurable
levels of DAB, which result from endogenous peroxidase
activity and non-specific antibody binding, each strategy was
designed to compensate for this background staining level.
1. A positivity index based on nuclear ER content was
calculated as the percentage of nuclei in the monoclonal
antibody-stained cytospin above a threshold point denoting
the background staining level. To determine the threshold
point for the background, the absolute upper limit of the
range of IOD values in the control preparation gave a poor
estimate due to variable presence of low frequencies of
densely stained nuclei. Consequently, the threshold was
calculated as the upper 95th percentile point of the frequency
distribution of IOD measurements of nuclei of the control.
This provided an IOD value for which 95% of the nuclei
below this point in the positive preparation would have a
background, or negative, staining level. The positivity index
was then calculated as the percentage of nuclei in the
positive preparation above this threshold value (Figure 1).
The 5% error involved in scoring some of the negative nuclei
as positive is negated by a similar overlap of positive nuclei
scored as negative. The degree of this overlap and relative
proportions of incorrectly scored nuclei could not be
determined.
2. A similar positivity index expressed as a percentage of
positive nuclei above an IOD threshold was calculated as for
the percentile method. However, the threshold IOD value
was calculated as a 95% probability level for the distribution
of frequencies of nuclear IOD in the control preparation.
Below this point, a nucleus in the positive preparation could
be identified as negative with 95% confidence. The selection
criteria were therefore based on statistical assumptions rather
than arbitrary choice of cut-off point as for the percentile
method. In each control preparation, the assumption was
made that the distribution of nuclear IOD was normal,
although most histograms indicated skew (e.g. Figure 1). A
positivity index of the percentage of nuclei in the positive
preparation was calculated as for the percentile method.
3. A positivity index based on integrated density of
staining (ER content) was calculated as the mean IOD of
DAB per nucleus. The level of background staining was
compensated for by subtracting the mean IOD of the nuclei
in the control preparation from the mean IOD of the nuclei
in the positive preparation. The positivity index, expressed in
the pixel units of the image analyser, was termed the 'SSCORE
4. A similar positivity index was calculated from the mean
IOD of DAB per nucleus. However, the background staining
was compensated for by dividing the mean IOD of nuclei in
the positive preparation by the mean IOD of nuclei in the
control. The positivity index, expressed as the ratio of
positive DAB IOD and negative DAB IOD was termed the
IDSCORE-
5. A positivity index based on staining density (ER
concentration) was calculated from the mean optical density
of DAB per nucleus. The background staining was
compensated for by subtracting the mean optical density of
the nuclei in the control preparation from that of the
positive preparation. The positivity index was termed the
SSCORE'
6. A similar positivity index was calculated from the mean
optical density of DAB staining per nucleus. However, the
background staining was compensated for by dividing the
mean optical density of stain in nuclei of the positive
preparation by the mean optical density of stain in nuclei of
the control. The positivity index was termed the DSCORE.
Statistical analyses
Association between the ER concentrations of the patient
cancer series as measured by the radioligand binding assay
and the various video image analysis indices was tested by
Pearson's correlation coefficient. The lines of best fit for the
comparisons of ER determined by various methods were
calculated by least squares analysis. Analysis of the
concordance rate in determination of receptor status was
performed using x2 tables.
Table I Oestrogen receptor values for individual primary
breast cancer patients as determined by DCC and image
analysis
Patient Percentage Percentage
no. DCCa ER-positiveb ER-positivec
1 219 63 61
2 37 8 7
3 156 26 39
4 62 51 53
5 13 13 11
6 347 87 85
7 225 8 6
8 238 5 5
9 214 32 33
10 336 38 30
11 73 3 6
12 35 1 2
13 207 9 14
14 67 34 29
15 180 29 37
16 158 57 55
17 263 51 54
18 65 33 34
19 88 37 33
20 34 34 35
21 31 3 3
22 45 27 24
23 64 16 15
24 372 57 49
25 100 24 23
26 42 5 8
27 218 22 24
28 0 0 0
29 0 2 2
30 0 0 0
31 0 0 0
32 0 0 0
33 0 0 0
34 0 0 0
35 0 0 0
All patients were infiltrating ductal carcinoma not
otherwise specified (NOS) with the exception of patients 11
(invasive lobular) and 29 (medullary).
'ER fmolmg-' cytosol protein by dextran coated charcoal
assay. 'Using 95th percentile of control for background
binding. cUsing 95% probability level for background binding.
A minimum of 250 nuclei were assessed by image analysis
on both primary antibody and control antibody-stained
cytospins.VIDEO IMAGE ANALYSIS OF OESTROGEN RECEPTORS 131
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Figure 1 Examples ofimage analysis profiles ofER immunocytochemical staining for four patients. Filled bars indicate frequency of
nuclei staining with defined integrated optical density of diaminobenzidine (DAB) on primary monoclonal antibody-stained
cytospins. Open bars indicate frequency of stained nuclei on control antibody-stained cytospins. The arrow in each case indicates
the threshold of positive immunostaining calculated by the 95th percentile method for the control slide. Percentage ER positivity:
a, 63%; b, 87%; c, 51%; d, 0%.
Results
The primary breast cancer patients in this study were
predominantly of NOS infiltrating ductal carcinoma histo-
pathology (Table I). A breakdown of the oestrogen receptor
quantitation by the DCC assay and the percentage ERICA-
positive nuclei using the 95th percentile and 95% probability
level methods to account for background binding is also
presented for the individual patients in Table I. Figure 1
comprises several representative histograms of ERICA-
stained needle aspirates employing the 95th percentile for
background staining and illustrating the variability of
nuclear staining between individual cancers. The histogram
for patient no. 1 is illustrated in Figure la and indicates two
major populations of nuclei on the primary antibody-stained
slide, one corresponding to the control population of
unstained nuclei and an additional population of ER-
containing nuclei. Approximately two-thirds of the nuclei
stained positive for ER in this patient, with high levels of
ER also detected by the biochemical assay (219fmolmg-1
cytosol protein). In patient no. 6 (Figure lb) almost 90% of
the nuclei contained ER, with approximately two-thirds
staining for low levels and one-third for high levels of ER.
This patient was also among the higher biochemically
determined values of ER for this series of patients
(347 fmolmg-1). Patient no. 4 (Figure lc) was an interesting
case. No discrete peak of ER-staining nuclei was apparent
but instead a population of tumour nuclei with broad
heterogeneity in expression of ER. Fifty per cent of the
tumour nuclei stained positively for ER. Figure ld illustrates
the histogram for patient no. 32, where no nuclei of the
primary antibody-stained aspirate had DAB levels greater
than the nuclei of the control antibody-stained aspirate. The
biochemical determination for this biopsy was also negative
(Ofmolmg -1).
The relationship between the number of ER-positive nuclei
for each individual case, as calculated using 95th percentiles
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Figure 2 Association between percentage ER-positive nuclei for
all cases, calculated by 95th percentiles and 95% probability
levels (r = 0.98; P < 0.0005). 95% confidence limits for the line of
best fit are indicated.
and 95% probability levels, is shown in Figure 2. The line of
best fit was calculated and indicated a high correlation
(r = 0.98; P < 0.0005).
The frequency distribution of tumours with varying
percentages of ER-positive nuclei using 95th percentiles is
illustrated in Figure 3. The frequencies are not normally
distributed about a mean but appear to be evenly
distributed, predominantly below 40% ER-positive cells.
Only six of the 28 ER-positive cancers had greater than 40%
ER-positive nuclei.
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Table III Categorisation of receptor status of breast cancer cases as
analysed by DCC and image analysis
Saturation analysis of cytosolic
radioligand binding (DCC)
Positivea Negative
Image analysis of Positiveb 24 0
fine needle aspirate Negative 3 8
x2=23.17 P<0.001
Threshold values: a> 10fmolmg-1. b >5% ER-positive nuclei.
0 20 40 60 80
Percentage ER-positive nuclei (95th percentiles)
Figure 3 Frequency distribution of percentage ER-positive
nuclei for all patient cancers.
Table II Association between ER determination by DCC and
image analysis indices
Pearson's correlation Probability
Image analysis index coeficient, r level, P
IOD 95th percentile 0.617 <0.001
IODC 95% probability level 0.590 <0.001
ISSCORE 0.383 <0.05
IDSCORE 0.062 =0.74
SSCORE 0.345 =0.07
DSCORE 0.017 =0.57
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Figure 4 Association between percentage ER-positive nuclei by
image analysis using 95th percentiles, and ER concentration by
radioligand binding assay (DCC) for all patient cancers (r = 0.77;
P <0.0005). 95% confidence limits for the line of best fit are
indicated.
The association between ER determination by the
standard DCC method and the various image analysis
indices is indicated in Table II. Significant associations
(P<0.001) were obtained by the 95th percentile and 95%
probability level methods for determining percentage of
tumour nuclei with an IOD for ER above that of
background. Similarly, subtraction of mean IOD for the
control population of nuclei from the IOD of the ERICA
primary antibody-stained nuclei (ISScORE) yielded a
statistically significant association. However, image analysis
indices based either on a division of mean IOD for the
Table IV Sensitivity, specificity and predictive value of image
analysis compared to biochemical assay (DCC)
Predictive Predictive
Concordancea Sensitivityb Specificityc value+d value -
32/35 24/27 8/8 24/24 8/11
(91%) (89%) (100%) (100%) (73%)
Threshold value for ER positivity: Biochemical assay >
10fmolmg-1; Image analysis >5% ER-positive nuclei.
aConcordance =(TP +TN)/(TP + FP + TN + FN) x 100%.
bSensitivity =TP/(TP + FN) x 100%.
cSpecificity = TN/(TN + FP) x 100%.
dPredictive value of a positive result =TP/(TP + FP) x 100%.
ePredictive value of a negative result =TN/(TN + FN) x 100%.
TP, true positive; FP, false positive; TN, true negative; FN, false
negative.
primary antibody-stained population by the control
population IOD, or on staining intensity (mean optical
density rather than integral optical density) of the nucleus,
failed to show significant association with the ER value
determined by the DCC method (Pearson's correlation
coefficient).
The relationship between the percentage of ERICA-
positive nuclei in the needle aspirate, as determined by video
image analysis using the 95th percentile method to account
for control staining, and the biochemical quantification of
the surgical biopsy for all 35 patients was examined in
Figure 4. The line of best fit by the least squares method was
calculated and indicated a high correlation (r = 0.77;
P < 0.0005). The assignment of threshold values of
10fmolmg-1 for the DCC receptor analysis and 5% ER-
positive cells by image analysis enabled determination of the
sensitivity (true positive ratio), specificity (true negative
ratio), concordance and predictive values for positivity and
negativity (McCarty et al., 1985). Using the thresholds
outlined above, the results shown in Tables III and IV were
obtained. Concordance of receptor status was 91%.
Discordance was seen in only three cases where tumours
were ER-positive by the biochemical assay and negative by
ER video image analysis, yielding a predictive value for
positive of 100% and predictive value for negative of 73%.
Sensitivity equalled 89% and specificity equalled 100%. This
association between ER positivity of breast cancers as
analysed by DCC and ERICA (Table III) was significant
(X2 =23.17, P <0.001).
Discussion
In this study of breast cancer patients the ERICA assay was
shown to have a concordance rate of 91% with the DCC
assay. Similar concordance rates have been reported by
Charpin et al. (1986), King et al. (1985), McCarty et al.
(1985) and Pertschuk et al. (1985) (88, 84, 91 and 86%
respectively). Compared with the DCC assay, image analysis
had a predictive value for a positive result of 100%, but only
73% for predicting negative results. This was attributed to
the 'incorrect' negative classification of several DCC-positive
tumours when an arbitrary ERICA threshold of 5% positive
nuclei was used. Reduction of this arbitrary threshold to 3%
positive nuclei improved the prediction of negative results to
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91%. To date there have been no large studies of the
relationship between ERICA results and response to
endocrine therapies in patients with advanced disease.
McClelland et al. (1986) demonstrated that ERICA predicted
outcome to therapy in 81% of 47 courses of treatment
(compared with 72% for the DCC assay). Similar results
showing the improved predictive ability of ERICA over the
DCC assay were also demonstrated by Pertschuk et al.
(1985) (80% versus 58%).
The majority of research groups performing ER immuno-
cytochemistry on frozen sections or fine needle aspirate have
employed a histological scoring index based on a
combination of visual analyses of the intensity of immuno-
staining and proportion of immunostained nuclei (King et
al., 1985; Pertschuk et al., 1985; Azavedo et al., 1986;
Flowers et al., 1986; Jonat et al., 1986). This approach can
lead to a high degree of subjectivity in the assessment of
staining intensity and hence the proportion of stained nuclei,
and this is difficult to control. The intra- and inter-observer
variation in assessments can be minimised by the use of a
computerised system of image analysis. To date there have
been few published reports of video image analysis applied
to the estimation of ER heterogeneity in breast cancer nuclei
(Charpin et al., 1986; Sklarew & Pertschuk, 1987; Franklin
et al., 1987). With these systems, background staining in
control populations of cells due to endogenous peroxidase
and non-specific antibody binding can be readily quantitated
by the computer system, thereby improving the reliability of
the measurements. In this study we considered several ways
to discriminate and compensate for background levels of
staining. The resultant positivity indices for each tumour
were then compared with the ER concentrations derived
using the DCC assay - currently the 'gold standard' for ER
quantitation. It appeared that the most reliable indices for
measuring ER-related deposition of stain in the needle
aspirates were those employing 95th percentiles or 95%
probability levels to identify for each specimen a unique
nuclear integrated optical density, below which staining
absorbance could be determined to be of control level.
Nuclei with integrated optical densities above this level were
deemed ER-positive and were graded accordingly. Indices
based solely on intensity of staining in fine needle aspirate
were unrelated to the biochemically determined ER
concentration. While the index based on a 95% probability
value for the control staining level is an acceptable statistical
technique, the alternative index based on percentiles proved
to be equally effective (Figure 2), possibly due to the high
skew of the nuclear IOD distributions. The percentile index
requires minimal computation and for this reason is the
technique of choice.
Quantitation of ER in fine needle aspirate of breast cancer
by video image analysis requires different assumptions to be
made than when analysing frozen sections. If one wishes to
measure the IOD of individual nuclei in frozen sections,
extensive programming is required to account for the fact
that the majority of cancer nuclei are not sectioned through
the greatest diameter of the cell - even if they all could be
assumed to be of the same size and shape. As observed by
Sklarew & Pertschuk (1987), an important consideration in
densitometry of sectioned material is the effect of nuclear
volume distribution on the observed receptor concentration
(mean optical density). Using nuclear volumes derived from
projected nuclear areas, these workers determined that the
presence of well-separated concentration peaks could not be
ascribed to differences in ER content, but were dependent on
variations in nuclear volume. Furthermore, in sectioned
material estimates of mean optical density were decreed as
'not always meaningful', which would agree with our obser-
vation for fine needle aspirate that mean optical density
measurements and oestrogen receptor quantitation by DCC
are not associated. While mathematic considerations of total
nuclear volume as determined for sectioned nuclei do not
apply to needle aspirates since the whole nucleus is available
for measurement, intensity of staining measurements will be
highly subject to nuclear area variations, due to technical
artefacts of cytocentrifugation. The statistical association of
integrated optical density measurements with the biochemical
ER determination for FN aspirates indicates, however, that
total ER content is far more important than ER concent-
ration. Hence, for assessment of FN aspirates at least,
greater accuracy in reporting will be achieved using indices
based on percentage ER-positive nuclei determined by image
analysis of nuclear IOD.
In one only wishes to determine whether a tumour is ER-
positive, then it appears that there is a strong correlation
between the ERICA and DCC techniques as indicated by the
concordance rates (Table IV), but when individual compari-
sons are made on single cancers significant quantitative
discrepancies can be observed, which need to be explained
(Figure 4). For example, why should two cancers with 50-
60% ER-positive cells have individual DCC values of
62 fmol mg-1 and 372 fmol mg-1; or conversely two tumour
cytosols with DCC values of approximately 200fmolmg-1
have values as disparate as 9% and 53% ER-positive cells?
Part of the answer may lie in cytosol preparation, which
leads to an averaging of ER concentration within the
extracted tissue. DCC quantitation is heavily dependent on
tumour cellularity and malignant to benign cell ratio. Theor-
etically then, one might expect significant variability to be
generated by the DCC assay and most investigators are
aware of this problem. Presently there is less certainty
regarding variability arising from immunocytochemical detec-
tion of ER. Currently, studies are in progress within our
laboratory to identify and eliminate potential sources of
variability in the preparation of immunocytochemically
stained cytospins of fine needle aspirate. Such studies will
enhance the acceptibility of ERICA and image analysis of
ER heterogeneity, and allow this new technology to super-
cede the more complex and less economic DCC assay.
Technically, at the present time all image analysis indices
are reliant on relative quantitation of DAB deposition and
no system exists for absolute quantitation of the number of
molecules of ER within individual cancer nuclei. However, it
is possible that systems based on microspheres with chemi-
cally coupled receptor, or cloned cell lines with constitutive
synthesis of ER from amplified gene constructs, may be
developed to assist in this quantitation.
One further point, which relates to the biological nature of
breast cancer disease, is raised by the frequency distribution
of percentage ER-positive nuclei in Figure 3. In this study
the majority (79%) of breast cancers examined had less than
40% ER-positive nuclei. This means that even in ER-positive
cancers, the majority of cells may not express oestrogen
receptors. Whether this absence of receptors is due to the
growth phase of the ER-positive cells, selection artefacts by
FNA, or a true ER-negative subpopulation needs to be
closely examined as this heterogeneity would have direct
prognosis implications for long-term clinical response to
endocrine therapy.
In conclusion, this study has demonstrated that video
image analysis of ERICA-stained nuclei obtained by fine
needle aspiration is an appropriate method for assigning ER
status in breast cancer. Furthermore this method is easy and
economic to perform, requiring only some cytological exper-
ience in the discrimination of tumour and benign cellular
elements.
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